REGN Stock Overview
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community Narratives
Narratives bring a range of perspectives from our community.
Innovative Therapies And Critical Market Expansions Fuel Biotech Growth
Regeneron Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1,144.77 |
| 52 Week High | US$1,211.20 |
| 52 Week Low | US$769.19 |
| Beta | 0.12 |
| 11 Month Change | 1.20% |
| 3 Month Change | 11.39% |
| 1 Year Change | 37.47% |
| 33 Year Change | 77.44% |
| 5 Year Change | 297.32% |
| Change since IPO | 5,319.03% |
Recent News & Updates
Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?
Sep 09
Regeneron Stock: Valuation Now Demands More Growth
Aug 26Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price
Aug 22Recent updates
Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?
Sep 09Regeneron Stock: Valuation Now Demands More Growth
Aug 26Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price
Aug 22Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Aug 04Regeneron's Robust Pipeline And Financial Health Signal Continued Growth
Aug 02Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings
Jul 11Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why
Jun 08These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well
May 21Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks
May 06Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing
Apr 30Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?
Apr 10Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate
Mar 26Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings
Feb 16Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024
Feb 10Regeneron's Push Into Obesity, Q4 2023 Earnings Review
Feb 02These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well
Jan 31Shareholder Returns
| REGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.1% | -1.9% | -3.4% |
| 1Y | 37.5% | 13.9% | 19.6% |
Return vs Industry: REGN exceeded the US Biotechs industry which returned 13.9% over the past year.
Return vs Market: REGN exceeded the US Market which returned 19.6% over the past year.
Price Volatility
| REGN volatility | |
|---|---|
| REGN Average Weekly Movement | 2.8% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: REGN has not had significant price volatility in the past 3 months.
Volatility Over Time: REGN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 13,926 | Leonard Schleifer | www.regeneron.com |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
Regeneron Pharmaceuticals, Inc. Fundamentals Summary
| REGN fundamental statistics | |
|---|---|
| Market cap | US$123.56b |
| Earnings (TTM) | US$4.32b |
| Revenue (TTM) | US$13.49b |
28.6x
P/E Ratio9.2x
P/S RatioIs REGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REGN income statement (TTM) | |
|---|---|
| Revenue | US$13.49b |
| Cost of Revenue | US$6.30b |
| Gross Profit | US$7.19b |
| Other Expenses | US$2.86b |
| Earnings | US$4.32b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 40.04 |
| Gross Margin | 53.27% |
| Net Profit Margin | 32.04% |
| Debt/Equity Ratio | 7.0% |
How did REGN perform over the long term?
See historical performance and comparison